INTRODUCTION: The randomized controlled trial "Physical Activity in Pediatric Cancer" determined the effects of an inhospital exercise intervention combining aerobic and muscle strength training on pediatric cancer patients with solid tumors undergoing neoadjuvant chemotherapy. METHODS:Participants were allocated to an exercise (n = 24, 17 boys; mean ± SEM age, 10 ± 1 yr) or control group (n = 25, 18 boys; 11 ± 1 yr). Training included three sessions per week for 19 ± 2 wk. Participants were assessed at treatment initiation, termination, and 2 months after end treatment. The primary endpoint was muscle strength (as assessed by upper and lower-body five-repetition-maximum tests). Secondary endpoints included cardiorespiratory fitness, functional capacity during daily life activities, physical activity, body mass and body mass index, and quality of life. RESULTS: Most sessions were performed in the hospital's gymnasium. Adherence to the program averaged 68% ± 4% and no major adverse events or health issues were noted. A significant interaction (group-time) effect was found for all five-repetition maximum tests (leg/bench press and lateral row; all P < 0.001). Performance significantly increased after training (leg press: 40% [95% confidence interval [CI], 15-41 kg); bench press: 24% [95% CI, 6-14 kg]; lateral row 25% [95% CI, 6-15 kg]), whereas an opposite trend was found in controls. Two-month post values tended to be higher than baseline for leg (P = 0.017) and bench press (P = 0.014). In contrast, no significant interaction effect was found for any of the secondary endpoints. CONCLUSION: An inhospital exercise program for pediatric cancer patients with solid tumors undergoingneoadjuvant treatment increases muscle strength despite the aggressiveness of such therapy.
RCT Entities:
INTRODUCTION: The randomized controlled trial "Physical Activity in Pediatric Cancer" determined the effects of an inhospital exercise intervention combining aerobic and muscle strength training on pediatric cancerpatients with solid tumors undergoing neoadjuvant chemotherapy. METHODS:Participants were allocated to an exercise (n = 24, 17 boys; mean ± SEM age, 10 ± 1 yr) or control group (n = 25, 18 boys; 11 ± 1 yr). Training included three sessions per week for 19 ± 2 wk. Participants were assessed at treatment initiation, termination, and 2 months after end treatment. The primary endpoint was muscle strength (as assessed by upper and lower-body five-repetition-maximum tests). Secondary endpoints included cardiorespiratory fitness, functional capacity during daily life activities, physical activity, body mass and body mass index, and quality of life. RESULTS: Most sessions were performed in the hospital's gymnasium. Adherence to the program averaged 68% ± 4% and no major adverse events or health issues were noted. A significant interaction (group-time) effect was found for all five-repetition maximum tests (leg/bench press and lateral row; all P < 0.001). Performance significantly increased after training (leg press: 40% [95% confidence interval [CI], 15-41 kg); bench press: 24% [95% CI, 6-14 kg]; lateral row 25% [95% CI, 6-15 kg]), whereas an opposite trend was found in controls. Two-month post values tended to be higher than baseline for leg (P = 0.017) and bench press (P = 0.014). In contrast, no significant interaction effect was found for any of the secondary endpoints. CONCLUSION: An inhospital exercise program for pediatric cancerpatients with solid tumors undergoing neoadjuvant treatment increases muscle strength despite the aggressiveness of such therapy.
Authors: Maxime Caru; Gabrielle Duhamel; Valérie Marcil; Serge Sultan; Caroline Meloche; Isabelle Bouchard; Simon Drouin; Laurence Bertout; Caroline Laverdiere; Daniel Sinnett; Daniel Curnier Journal: Support Care Cancer Date: 2019-10-16 Impact factor: 3.603
Authors: Martin Kaj Fridh Nielsen; Jesper Frank Christensen; Thomas Leth Frandsen; Troels Thorsteinsson; Lars Bo Andersen; Karl Bang Christensen; Peder Skov Wehner; Henrik Hasle; Lis Ørgaard Adamsen; Kjeld Schmiegelow; Hanne Bækgaard Larsen Journal: BMC Med Date: 2020-07-06 Impact factor: 8.775
Authors: Treya M Long; Shoshana R Rath; Karen E Wallman; Erin K Howie; Leon M Straker; Andrew Bullock; Thomas S Walwyn; Nicholas G Gottardo; Catherine H Cole; Catherine S Choong; Louise H Naylor Journal: PLoS One Date: 2018-08-09 Impact factor: 3.240
Authors: Paula A Ospina; Alyssa McComb; Lesley E Pritchard-Wiart; David D Eisenstat; Margaret L McNeely Journal: Cochrane Database Syst Rev Date: 2021-08-03
Authors: Francesca Lanfranconi; W Zardo; T Moriggi; E Villa; G Radaelli; S Radaelli; F Paoletti; E Bottes; T Miraglia; L Pollastri; P Vago; F Nichelli; M Jankovic; A Biondi; A Balduzzi Journal: Sci Rep Date: 2020-07-30 Impact factor: 4.379
Authors: Sabine Kesting; Peter Weeber; Martin Schönfelder; Bernhard W Renz; Henning Wackerhage; Irene von Luettichau Journal: Front Oncol Date: 2020-02-21 Impact factor: 6.244